US Patent

US8420629 — Azetidine and cyclobutane derivatives as JAK inhibitors

Method of Use · Assigned to Incyte Corp · Expires 2029-03-10 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects azetidine and cyclobutane derivatives as JAK inhibitors for treating JAK-associated diseases, including inflammatory and autoimmune disorders, and cancer.

USPTO Abstract

The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

Drugs covered by this patent

Olumiant (baricitinib) · Eli Lilly

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-247`	—	Olumiant
`U-247`	—	Olumiant

Patent Metadata

Patent number: US8420629
Jurisdiction: US
Classification: Method of Use
Expires: 2029-03-10
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.